Deutetrabenazine is a novel, highly selective VMAT2 inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease and TD (15). The gene discussed is SLC18A2; the disease is thanatophoric dysplasia.